Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022

Good morning. My name is Ambinod Dhakal, and I'm associate professor of medicine at Medical College of Wisconsin. So, in this ASC, we presented a study where we looked at the outcomes of patients with a lenin-romidofractory that were treated in deratomab clinical trials. In that study, we looked at all the patients that were treated on a clinical trial, including deratomab, for example, alzion, griffin, cassiopeia, polox, castor. And the goal of that is that the primary endpoint was to look at the outcome of patients at different lines of therapy after they were lenin-romidofractory. So there were patients in one line, two line, and three lines. And what we saw in that study was the response rates decreased with each line of therapy, and also both progression-free survival and oral survival decreased with each subsequent line of therapy. For example, the overall progression-free survival in these patients were about 9.3 months, but when you break down by the lines of therapy, it is 14 some months in the first line versus about 8.3 months in the third line. So that tells you that these patients have, in general, the very poor outcomes and would benefit from new treatments with the novel mechanism of action. The other study that we presented was a phase one interim analysis of first-in-human NK CAR against BCMA. So this is a very unique product where we used induced fluid protein stem cells to generate the CAR. And the CAR has three very unique engineering models, which included the BCMA NK CAR, knockout of CD38 because of the use of deratomab, and two other modifications included the fusion of the interleukin-15 for the persistence and the ST16 for the monoclonal antibody. So the study included two quarts of the patient. The first cohort included just NK infusion or Ft576, the product infusion by itself, either in a single dose or in two doses separated in two weeks apart. And then the other cohort included infusion along with the monoclonal antibody deratomab as per the standard schedule. So this is right now currently ongoing history in the dose escalation phase. We treated so far 10 patients in this study. And we saw that the product is safe so far. So far 300 million cells were the maximum dose that has been given in the level two dose. And then there is early responses already happening. And we're hoping that as we go in the higher doses, we will see some responses, antimyelome activity, and also some safety and data as well.